FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081663884> ?p ?o ?g. }

• W2081663884 endingPage "1158" @default.
• W2081663884 startingPage "1155" @default.
• W2081663884 abstract "Estradiol levels decline intermittently during the perimenopausal transition and permanently after menopause. As a consequence, women experience symptoms related to urogenital atrophy, vasomotor instability, neurocognitive dysfunction, accelerated bone loss, and cardiovascular disease. For some women, vasomotor instability and associated insomnia are disabling. Vasomotor instability causes symptoms of hot flashes resulting from disruption of temperature regulatory mechanisms and associated vasodilation. Three quarters of white women experience hot flashes during the perimenopausal transition, beginning on average 2 years before the cessation of menses. Eighty-five percent of these women continue to experience hot flashes for more than 1 year, and 25% to 50% for as long as 5 years.1Thompson B Hart SA Durno D Menopausal age and symptomatology in general practice.J Biosoc Sci. 1973; 5: 71-82Crossref PubMed Scopus (159) Google Scholar Hot flashes usually wane over time, but in some individuals they may continue indefinitely. Although demographic studies are incomplete, hot flashes appear to be more common in African American women than in their white, Hispanic, Japanese, or Chinese counterparts.2Avis NE Stellato R Crawford S et al.Is there a menopausal syndrome? menopausal status and symptoms across racial/ethnic groups.Soc Sci Med. 2001; 52: 345-356Crossref PubMed Scopus (489) Google Scholar Interestingly, detailed studies of Mayan Indian women revealed that they reported no symptoms associated with menopause, perhaps because of their cultural attitudes toward menopause.3Martin MC Block JE Sanchez SD Arnaud CD Beyene Y Menopause without symptoms: the endocrinology of menopause among rural Mayan Indians.Am J Obstet Gynecol. 1993; 168: 1839-1843Abstract Full Text PDF PubMed Scopus (75) Google Scholar During the perimenopausal transition, ovarian function is intermittent, with periods of diminished estradiol production followed by paradoxical increases.4Burger HG Dudley EC Robertson DM Dennerstein L Hormonal changes in the menopause transition.Recent Prog Horm Res. 2002; 57: 257-275Crossref PubMed Scopus (342) Google Scholar The periods of quiescent secretion and associated plasma estradiol decrements result in vasomotor instability. Hot flashes manifest as intense heat and intense sweating followed by a cold, clammy sensation. The frequency, duration, and intensity of the hot flashes vary in each individual. Hot flashes may last for 30 seconds or 5 minutes, with an average of approximately 4 minutes.5Meldrum DR Shamonki IM Frumar AM Tataryn IV Chang RJ Judd HL Elevations in skin temperature of the finger as an objective index of postmenopausal hot flashes: standardization of the technique.Am J Obstet Gynecol. 1979; 135: 713-717Abstract Full Text PDF PubMed Scopus (79) Google Scholar The frequency and severity may wax and wane in the same individual in response to unknown environmental and physiologic influences. Hot flashes result from estrogen withdrawal and occur in both men and women. Reductions of estradiol caused by natural menopause, surgical removal of the ovaries or testes, or use of gonadotropin-releasing hormone (GnRH) agonists or antagonists equally cause vasomotor instability. The precise pathophysiology of vasomotor instability is not fully understood but can be likened to a paroxysmal firing of the neurons in the temperature regulatory center. Probably as a result, a prodrome of rapid heart beat, dizziness, or faintness may occur. Vasodilation ensues and results in a visible ascending flush of the chest, neck, and face. The increase in peripheral blood flow is limited to the cutaneous vasculature, and systemic blood pressure does not change. Skin temperature increases, and the loss of body heat through the skin results in a decrease in core temperature.6Mashchak CA Kletzky OA Artal R Mishell Jr, DR The relation of physiological changes to subjective symptoms in postmenopausal women with and without hot flushes.Maturitas. 1984; 6: 301-308Abstract Full Text PDF PubMed Scopus (21) Google Scholar As a result of the firing of hypothalamic neurons, plasma catecholamines and luteinizing hormone levels rise immediately. Enhancement of neuronal firing in the reticular activating system results in awakening from sleep. There is an immediate lowering of the thermoregulatory set point in the hypothalamus, precipitated by estrogen withdrawal. The etiology is complex, as described by Shanafelt et al7Shanafelt TD Barton DL Adjei AA Loprinzi CL Pathophysiology and treatment of hot flashes.Mayo Clin Proc. 2002; 77: 1207-1218Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar in this issue of the Mayo Clinic Proceedings, and involves interactions among catecholamines, prostaglandins, endorphins, and other neuropeptides. For postmenopausal women, hot flashes are often most disruptive at night. When monitoring sleep with use of a sleep polygraph, Erlik et al8Erlik Y Tataryn IV Meldrum DR Lomax P Bajorek JG Judd HL Association of waking episodes with menopausal hot flushes.JAMA. 1981; 245: 1741-1744Crossref PubMed Scopus (262) Google Scholar found that changes in skin resistance and body temperature were associated with awakening. Frequent awakening can lead to chronic fatigue, irritability, mild depression, and changes in memory and attention span. The need to develop alternatives to estradiol for treatment of hot flashes has led to development of valid methodology to examine the efficacy of various pharmaceutical approaches. We now know that such studies require careful attention to stringent protocols to ensure the validity of the results. In interpreting the results of the available studies, several issues must be considered. In virtually all reported studies, hot flashes respond to placebo in 30% to 50% of women. A reduction in hot flashes also occurs in association with consultation with a health care provider. In response to a variety of factors, symptoms can vary from month to month. Accordingly, valid studies require a lead-in period before initiation of therapy, double-blind and crossover designs, use of a placebo control, and precise instruments for quantification of the frequency and severity of hot flash episodes. Until the past 5 years, most studies did not include such stringent experimental design. However, with the use of more rigorous experimental standards, several therapies have been shown conclusively to be effective. Less well studied agents must be considered only possibly effective. Estrogen in almost any form reduces the severity and frequency of hot flashes and diminishes sleep latency time and the number of episodes of awakening. Notwithstanding deficiencies in experimental design, estrogen therapy is considered definitely effective on the basis of its nearly uniform (ie, 96%) efficacy regarding these end points. Estrogen therapy is contraindicated in many women, and others are fearful of its adverse effects and prefer other approaches. These considerations provided an impetus for finding safe nonhormonal alternatives to attenuate hot flashes. The recent results of the Women's Health Initiative9Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333Crossref PubMed Scopus (13969) Google Scholar provided additional incentive to identify means to alleviate hot flashes without using estrogen. As a result, many newer compounds have been tested in clinical trials for their dampening effects on vasomotor instability. A review of past studies uncovers many agents used for hot flashes but not subjected to rigorous testing in clinical trials. The progestins, such as depomedroxyprogesterone acetate (MPA), were incidentally noted to attenuate hot flashes in women with endometrial cancer. At doses of 150 mg every 1 to 2 months, reduction in hot flashes is up to 85%, comparable to the reduction with estrogen.10Morrison JC Martin DC Blair RA et al.The use of medroxyprogesterone acetate for relief of climacteric symptoms.Am J Obstet Gynecol. 1980; 138: 99-104Abstract Full Text PDF PubMed Scopus (76) Google Scholar Oral MPA (10 mg/d) reduces hot flash frequency by 87%.11Albrecht BH Schiff I Tulchinsky D Ryan KJ Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.Am J Obstet Gynecol. 1981; 139: 631-635Abstract Full Text PDF PubMed Scopus (62) Google Scholar Concerns have been raised about the use of MPA because of the recent publication of the Women's Health Initiative results.9Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333Crossref PubMed Scopus (13969) Google Scholar Adverse effects of mastalgia, mood changes, bloating, weight gain, and irregular vaginal bleeding also limit routine use of progestins. Reports suggest that antihypertensive agents such as the α-adrenergic agonists (clonidine, 0.05-0.2 mg/d; lofexidine, 0.1 mg/d; methyldopa, 250 mg 3 times daily) also reduce hot flashes by 20% to 65%.12Jones KP Ravnikar V Schiff I A preliminary evaluation of the effect of lofexidine on vasomotor flushes in post-menopausal women.Maturitas. 1985; 7: 135-139Abstract Full Text PDF PubMed Scopus (10) Google Scholar, 13Laufer LR Erlik Y Meldrum DR Judd HL Effect of clonidine on hot flashes in postmenopausal women.Obstet Gynecol. 1982; 60: 583-586PubMed Google Scholar, 14Hammond MG Hatley L Talbert LM A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes.J Clin Endocrinol MetaB. 1984; 58: 1158-1160Crossref PubMed Scopus (43) Google Scholar These agents may work by altering neurotransmitters in the hypothalmus that regulate the thermoregulatory center. The frequent adverse effects of dizziness and dry mouth make these agents unpopular with perimenopausal women. The percentage of women who experience a benefit and the degree of reduction in severity of hot flashes with these agents are clearly less than with estrogen. Veralipride is a first cousin of cisapride, which has been approved for the treatment of hot flashes in several countries, and compared favorably with estrogen.15Wesel S Bourguignon RP Bosuma WB Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes.Curr Med Res Opin. 1984; 8: 696-700Crossref PubMed Scopus (25) Google Scholar However, the occurrence of central nervous system adverse effects such as tremor and pseudoparkinsonian symptoms has limited the use of this agent. One of the older preparations on the market is Bellergal, a combination of ergotamine tartrate, belladonna alkaloids, and phenobarbital (40 mg) that reduces hot flashes by 60% compared to a placebo reduction rate of 22% if given twice daily.16Lebherz TB French L Nonhormonal treatment of the menopausal syndrome: a double-blind evaluation of an autonomic system stabilizer.Obstet Gynecol. 1969; 33: 795-799PubMed Google Scholar This drug has been described as an “autonomic system stabilizer” and inhibits the sympathetic-parasympa-thetic pathway. However, the potential for addiction limits its usefulness. Vitamin E was thought to reduce hot flashes and atrophic vaginitis as early as the 1940s. A well-designed trial17Barton DL Loprinzi CL Quella SK et al.Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.J Clin Oncol. 1998; 16: 495-500Crossref PubMed Scopus (345) Google Scholar showed a 30% reduction in hot flashes with placebo and 40% with vitamin E. This result was statistically significant but of dubious clinical utility. Flavonoids such as hesperidin, combined with vitamin C, have been used to manage hot flashes. Offensive body odor and a tendency for perspiration to stain clothing permanently are unwelcome adverse effects. Several classes of herbal remedies have been studied for their effects on hot flashes. Most have not been subjected to rigorous study, whereas others appear to exert no demonstrable benefit. For example, dong quai, an herbal preparation derived from the root of Angelica sinensis, was equivalent to placebo in attenuating hot flashes in a well-controlled study.18Hirata JD Swiersz LM Zell B Small R Ettinger B Does dong quai have estrogenic effects in postmenopausal women? a double-blind, placebo-controlled trial.Fertil Steril. 1997; 68: 981-986Abstract Full Text PDF PubMed Scopus (208) Google Scholar Dong quai contains coumarin-like substances and should be avoided in patients receiving anticoagulation, those with bleeding diatheses, or those taking aspirin or nonsteroidal anti-inflammatory agents.19Page II, RL Lawrence JD Potentiation of warfarin by dong quai.Pharmacotherapy. 1999; 19: 870-876Crossref PubMed Scopus (153) Google Scholar Licorice root (Glycyrrhiza glabra) has been used for premenstrual syndrome for thousands of years, and its effects have been attributed to increasing progesterone levels while lowering estrogen levels, imitating the effects of a progestogen. Licorice has been used to treat Addison disease because glycyrrhiza in licorice root blocks 11β-dehydrogenase, the enzyme that converts cortisol to cortisone. No controlled studies have been done with this compound in menopausal women. Similar problems (lack of placebo-controlled, adequately powered clinical trials) or lack of efficacy in controlled trials plague other compounds such as red clover extract (Trifolium pratense) and wild yam creams (Dioscorea villosa). Evening primrose (evening star) contains linoleic acid, an omega-3 essential fatty acid. In a well-designed clinical trial with adequate placebo control, evening primrose oil had no effect on the symptoms associated with hot flashes.20Chenoy R Hussain S Tayob Y O'Brien PM Moss MY Morse PF Effect of oral gamolenic acid from evening primrose oil on menopausal flushing.BMJ. 1994; 308: 501-503Crossref PubMed Scopus (160) Google Scholar Magnetic therapy is not useful,21Carpenter JS Wells N Lambert B et al.A pilot study of magnetic therapy for hot flashes after breast cancer.Cancer Nurs. 2002; 25: 104-109Crossref PubMed Scopus (37) Google Scholar and acupuncture has been studied in a limited fashion.22Dong H Ludicke F Comte I Campana A Graff P Bischof P An exploratory pilot study of acupuncture on the quality of life and reproductive hormone secretion in menopausal women.J Altern Complement Med. 2001; 7: 651-658Crossref PubMed Scopus (62) Google Scholar The best studied natural product is Cimicifuga racemosa or black cohosh (snakeroot, bugbane); however, rigorous trials are lacking, and results are inconsistent. The German Botanical Regulatory Body has approved black cohosh for treating symptoms of the climacteric, and treatment is reimbursed. Use is recommended for no more than 6 months at doses of 20 to 40 mg/d. Although studies of black cohosh in breast cancer survivors do not show impressive results, concurrent treatment with a selective estrogen receptor antagonist (SERM), tamoxifen, may have altered the results because of competitive interactions at the estrogen receptor. Studies in women who are not taking an SERM suggest a 25% to 30% improvement over placebo in the attenuation of hot flashes.23Duker EM Kopanski L Jarry H Wuttke W Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats.Planta Med. 1991; 57: 420-424Crossref PubMed Scopus (142) Google Scholar Soy protein, or the isolated isoflavones extracted from soy, has been an area of intense interest in preventing menopausal symptoms.24Vincent A Fitzpatrick LA Soy isoflavones: are they useful in menopause?.Mayo Clin Proc. 2000; 75: 1174-1184Abstract Full Text Full Text PDF PubMed Scopus (139) Google Scholar The isoflavones genistein and daidzein have estrogen-like effects on select target tissues. One study compared soy flour to wheat flour. The group ingesting wheat flour had a 25% reduction in hot flashes, consistent with the placebo effect in other studies. The group ingesting soy flour had a 40% reduction in hot flashes.25Murkies AL Lombard C Strauss BJ Wilcox G Burger HG Morton MS Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat.Maturitas. 1995; 21: 189-195Abstract Full Text PDF PubMed Scopus (383) Google Scholar Most other studies using soy protein or isolated phytoestrogens have not noted dramatic differences from those achieved with placebo. Other phytoestrogen-containing foods include fennel, celery, parsley, nuts, whole grains, apples, and alfalfa. Patients assume that if a product is made from “natural” herbs, then it is not only safe but also desirable for its health benefits. Consumers assume that these products are not harmful and that they have established efficacy data. However, many problems arise during the manufacturing process, and products often are inconsistent from batch to batch. There are no requirements for thorough studies for safety and efficacy because current regulations put the burden of proof of harm on the consumer, not the company providing the product. In addition, many of these products may have estrogen-like effects, which are relevant in patients with estrogen-dependent tumors, and their safety is unknown. A recent study of human breast tumors in nude mice showed that the 2 most potent soy components, genistein and daidzein, stimulated tumor growth and antagonized the beneficial effects of tamoxifen.26Ju YH Doerge DR Allred KF Allred CD Helferich WG Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.Cancer Res. 2002; 62: 2474-2477PubMed Google Scholar A major recent advance regarding treatment of hot flashes was the development of rigorous methodology for studying various agents. This methodology was reviewed recently in the Journal of Clinical Oncology?27Sloan JA Loprinzi CL Novotny PJ Barton DL Lavasseur BI Windschitl H Methodologic lessons learned from hot flash studies.J Clin Oncol. 2001; 19: 4280-4290Crossref PubMed Scopus (392) Google Scholar Key factors in experimental design included careful patient selection, placebo controls, double-blind and double-dummy design, a lead-in period to counter the initial health care encounter effect, and crossover trial designs. Loprinzi (a coauthor of the article on treating hot flashes with gabapentin published in this issue of the Mayo Clinic Proceedings28Loprinzi CL Barton DL Sloan JA et al.Pilot evaluation of gabapentin for treating hot flashes.Mayo Clin Proc. 2002; 77: 1159-1163Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar) spearheaded the development of these clinical trial designs. Using this methodology, he showed that several alternatives to estrogen are definitely effective for treating hot flashes. With this methodology, it will now be possible to test agents such as gabapentin, which appear from observational studies to be promising. The first of the agents for hot flashes shown to be definitely effective in a rigorous clinical trial was megestrol acetate. Loprinzi et al29Loprinzi CL Pisansky TM Fonseca R et al.Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.J Clin Oncol. 1998; 16: 2377-2381Crossref PubMed Scopus (250) Google Scholar showed that megestrol acetate is highly effective for treating hot flashes in both men and women. Several trials then demonstrated the efficacy of the selective serotonin reuptake inhibitor (SSRI) class of drugs for hot flashes. Of this class, paroxetine, fluoxetine, and venlafaxine all appear efficacious. A large North Central Cancer Treatment Group multicenter trial showed the efficacy of venlafaxine. The frequency and severity of hot flashes decreased by 75% vs a 30% response with placebo.30Loprinzi CL Kugler JW Sloan JA et al.Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.Lancet. 2000; 356: 2059-2063Abstract Full Text Full Text PDF PubMed Scopus (675) Google Scholar Clearly not as effective as estrogens for hot flashes, these agents provide substantial relief of symptoms in women in whom estrogens are contraindicated or unacceptable. These agents also relieve the symptoms of mild depression, which may accompany menopause and vasomotor instability. One adverse effect is sexual dysfunction, which can occur in 7% to 30% of persons taking an SSRI.31Clayton AH Pradko JF Croft HA et al.Prevalence of sexual dysfunction among newer antidepressants.J Clin Psychiatry. 2002; 63: 357-366Crossref PubMed Scopus (473) Google Scholar In this issue of the Mayo Clinic Proceedings, Shanafelt et al7Shanafelt TD Barton DL Adjei AA Loprinzi CL Pathophysiology and treatment of hot flashes.Mayo Clin Proc. 2002; 77: 1207-1218Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar indicate in a non-placebo-controlled trial that gabapentin may be a useful adjuvant for treating hot flashes in perimenopausal patients. This result deserves attention and further scientific scrutiny because the investigators have extensive experience in clinical trials studying the effects of drugs on hot flashes. This perspective allows one to infer that it is likely that placebo-controlled trials will confirm these results. Gabapentin is an anticonvulsant structurally related to the neurotransmitter γ-aminobutyric acid (GABA), but it does not interact with GABA receptors, is not converted metabolically into GABA or a GABA agonist, and is not an inhibitor of GABA uptake or degradation. The mechanism of action is not well established, and preliminary trials suggest that it may be useful in bipolar disorders. The central nervous system neurotransmitter effects of gabapentin may be responsible for reducing the frequency of hot flashes. Gabapentin has been approved for use in France for postherpetic neuralgia. Other possible indications for gabapentin include alcohol withdrawal and anxiety. In a recently published clinical trial in men with prostate cancer who were treated with GnRH analogues and antiandrogens, the disabling hot flashes were successfully treated with gabapentin.32Jeffery SM Pepe JJ Popovich LM Vitagliano G Gabapentin for hot flashes in prostate cancer.Ann Pharmacother. 2002; 36: 433-436Crossref PubMed Scopus (30) Google Scholar Unfortunately, gabapentin has been associated with anorgasmy in both men and women.33Grant AC Oh H Gabapentin-induced anorgasmia in women [letter].Am J Psychiatry. 2002; 159: 1247Crossref PubMed Scopus (3) Google Scholar Nonetheless, a thorough study of gabapentin in rigorous clinical trials is now warranted. Clearly, the ideal treatment for hot flashes has not been found, and breast cancer survivors may be particularly difficult to treat because of the concurrent use of an SERM. A multifactorial approach is recommended. Advice to patients should include keeping a diary of hot flashes to look for “triggers.” Regular exercise helps to reduce hot flashes,34Ivarsson T Spetz AC Hammar M Physical exercise and vasomotor symptoms in postmenopausal women.Maturitas. 1998; 29: 139-146Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar as does avoiding spicy foods and alcohol. Wearing layered clothing can help because layers can be removed or added easily. Keeping ambient temperature low has also been suggested. Venlafaxine, the most thoroughly studied agent, is the first pharmacological choice. Clonidine patches and megestrol acetate are considered second-line treatment. Finally, some women, after being fully informed about risks and benefits, will choose to take estrogens (or an herbal product with estrogen-like activity) if all other treatments fail. Clearly, vasomotor instability is a common clinical problem. It is based on a pathophysiology that involves disruption of normal neuronal regulatory processes. Intensive study of the pathophysiology is needed to develop more effective nonhormonal therapies. Fortunately, validated clinical instruments are available for testing the efficacy of newly identified agents. We must learn the basic mechanisms underlying vasomotor instability so that a rational approach can be used to design effective treatment. Pilot Evaluation of Gabapentin for Treating Hot FlashesMayo Clinic ProceedingsVol. 77Issue 11PreviewTo obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Full-Text PDF Pathophysiology and Treatment of Hot FlashesMayo Clinic ProceedingsVol. 77Issue 11PreviewHot flashes affect about three fourths of postmenopausal women and are one of the most common health problems in this demographic group. Dysfunction of central thermoregulatory centers caused by changes in estrogen levels at the time of menopause has long been postulated to be the cause of hot flashes. Treatment should begin with a careful patient history, with specific attention to the frequency and severity of hot flashes and their effect on the individual's function. For mild symptoms that do not interfere with sleep or daily function, behavioral changes in conjunction with vitamin E (800 IU/d) use is a reasonable initial approach. Full-Text PDF" @default.
• W2081663884 created "2016-06-24" @default.
• W2081663884 creator A5081817848 @default.
• W2081663884 creator A5086493873 @default.
• W2081663884 date "2002-11-01" @default.
• W2081663884 modified "2023-09-23" @default.
• W2081663884 title "Hot Flashes: The Old and the New, What Is Really True?" @default.
• W2081663884 cites W1532065599 @default.
• W2081663884 cites W1532687908 @default.
• W2081663884 cites W1593442063 @default.
• W2081663884 cites W1604937352 @default.
• W2081663884 cites W1865738444 @default.
• W2081663884 cites W1891596808 @default.
• W2081663884 cites W1935573162 @default.
• W2081663884 cites W1965503655 @default.
• W2081663884 cites W1968365703 @default.
• W2081663884 cites W1975800838 @default.
• W2081663884 cites W1983795212 @default.
• W2081663884 cites W1994058854 @default.
• W2081663884 cites W1995121929 @default.
• W2081663884 cites W2008737066 @default.
• W2081663884 cites W2022361277 @default.
• W2081663884 cites W2024733475 @default.
• W2081663884 cites W2025352687 @default.
• W2081663884 cites W2044439690 @default.
• W2081663884 cites W2065878617 @default.
• W2081663884 cites W2076559704 @default.
• W2081663884 cites W2077665587 @default.
• W2081663884 cites W2082854214 @default.
• W2081663884 cites W2084667980 @default.
• W2081663884 cites W2087724126 @default.
• W2081663884 cites W2092049538 @default.
• W2081663884 cites W2107551305 @default.
• W2081663884 cites W2111625981 @default.
• W2081663884 cites W2124569831 @default.
• W2081663884 cites W2133675074 @default.
• W2081663884 cites W2136137449 @default.
• W2081663884 cites W2146789092 @default.
• W2081663884 doi "https://doi.org/10.4065/77.11.1155" @default.
• W2081663884 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12440549" @default.
• W2081663884 hasPublicationYear "2002" @default.
• W2081663884 type Work @default.
• W2081663884 sameAs 2081663884 @default.
• W2081663884 citedByCount "13" @default.
• W2081663884 countsByYear W20816638842012 @default.
• W2081663884 countsByYear W20816638842013 @default.
• W2081663884 countsByYear W20816638842016 @default.
• W2081663884 countsByYear W20816638842019 @default.
• W2081663884 countsByYear W20816638842020 @default.
• W2081663884 countsByYear W20816638842022 @default.
• W2081663884 crossrefType "journal-article" @default.
• W2081663884 hasAuthorship W2081663884A5081817848 @default.
• W2081663884 hasAuthorship W2081663884A5086493873 @default.
• W2081663884 hasBestOaLocation W20816638841 @default.
• W2081663884 hasConcept C177713679 @default.
• W2081663884 hasConcept C71924100 @default.
• W2081663884 hasConceptScore W2081663884C177713679 @default.
• W2081663884 hasConceptScore W2081663884C71924100 @default.
• W2081663884 hasIssue "11" @default.
• W2081663884 hasLocation W20816638841 @default.
• W2081663884 hasLocation W20816638842 @default.
• W2081663884 hasOpenAccess W2081663884 @default.
• W2081663884 hasPrimaryLocation W20816638841 @default.
• W2081663884 hasRelatedWork W1506200166 @default.
• W2081663884 hasRelatedWork W1995515455 @default.
• W2081663884 hasRelatedWork W2048182022 @default.
• W2081663884 hasRelatedWork W2080531066 @default.
• W2081663884 hasRelatedWork W2604872355 @default.
• W2081663884 hasRelatedWork W2748952813 @default.
• W2081663884 hasRelatedWork W2899084033 @default.
• W2081663884 hasRelatedWork W3031052312 @default.
• W2081663884 hasRelatedWork W3032375762 @default.
• W2081663884 hasRelatedWork W3108674512 @default.
• W2081663884 hasVolume "77" @default.
• W2081663884 isParatext "false" @default.
• W2081663884 isRetracted "false" @default.
• W2081663884 magId "2081663884" @default.
• W2081663884 workType "article" @default.